Signature Equity Partners’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Signature Equity Partners's VRTX Position: Q2 2026 in Review
Signature Equity Partners reduced its Vertex Pharmaceuticals (VRTX) stake by 85% in Q2 2026, selling an estimated $131K and leaving 51 shares worth $25.3K. The position accounts for 0.01% of the portfolio, ranked #590.
Signature Equity Partners first reported a position in VRTX in Q4 2025 and has held it in 3 quarters since. The position peaked at $155K in Q1 2026. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Signature Equity Partners held 51 shares of Vertex Pharmaceuticals worth $25.3K as of Q2 2026.
- Signature Equity Partners sold 296 Vertex Pharmaceuticals shares in Q2 2026, an estimated $131K.
- Vertex Pharmaceuticals made up 0.01% of Signature Equity Partners's portfolio in Q2 2026, its #590 holding.
- Signature Equity Partners first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
- Signature Equity Partners's Vertex Pharmaceuticals position peaked at $155K in Q1 2026.
- 1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Signature Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.